Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2019-10-25 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
2019年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement for the 2019 first extraordinary shareholders' meeting of Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the meeting's convening, attendance, voting results on proposals, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on the official results of shareholder votes at a general meeting, including vote counts and percentages for each proposal. There is no financial data, no presentation materials, no management discussion, nor is it a report publication announcement. The document is clearly an official announcement of voting results from a shareholders' meeting, matching the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 2603 characters, which is relatively short but contains detailed voting results, not just a notice of report publication or a brief announcement. Therefore, the correct classification is DVA with high confidence.
2019-10-25 Chinese
关于召开2019年第一次临时股东大会的提示性公告
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed announcement regarding the convening of the 2019 first extraordinary general meeting (临时股东大会) of Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes information about the meeting date, voting procedures (both onsite and online), agenda items (including a proposal to change the company’s business scope and amend the articles of association, and a proposal to change the 2019 audit firm), registration details, and proxy voting instructions. The document does not contain financial statements or results but is a formal notice to shareholders about the meeting and how to participate and vote. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings. The document length (5414 characters) and content confirm it is not a brief announcement or a report publication announcement but a full solicitation document for shareholder voting.
2019-10-21 Chinese
回购报告书
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement from Shenzhen Xintai Pharmaceutical Co., Ltd. regarding a share repurchase plan. It includes specifics about the purpose, amount, price limits, implementation period, funding source, and risk factors related to the share buyback. It also contains the board's authorization, independent directors' opinions, and compliance with relevant laws and regulations. The document is not a financial report, earnings release, or management discussion but a formal disclosure about the company's intention and plan to repurchase its own shares. This fits the definition of a Transaction in Own Shares (POS) filing, which covers share repurchase announcements and related details.
2019-10-17 Chinese
关于子公司获得注射用重组特立帕肽药品注册批件的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding its subsidiary receiving a drug registration approval from the National Medical Products Administration. It details the drug's specifications, approval number, and market potential. The document is short (1173 characters) and serves as an official announcement of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management changes. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under a general regulatory announcement category.
2019-10-15 Chinese
关于控股股东股权质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the pledge of shares by the controlling shareholder of Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the number of shares pledged, pledge dates, pledgees, and the proportion of shares pledged relative to total holdings. The document is an announcement of a financing-related event involving share pledges, not a full financial report or audit. It does not contain financial statements or detailed financial analysis. The content fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as share pledges.
2019-10-14 Chinese
关于回购股份事项前十名股东持股情况的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from Shenzhen Xintai Pharmaceutical Co., Ltd. regarding the shareholding situation of the top ten shareholders before a share repurchase plan. It details the number and percentage of shares held by the top shareholders and the top unrestricted shareholders as of a specific date. The document references a board meeting approving a share repurchase plan and provides shareholder information as required by Shenzhen Stock Exchange rules. The content focuses on shareholding details related to a share buyback and does not contain financial statements, earnings data, or management discussion. It is not a full report but an announcement related to capital structure changes, specifically share repurchase. Therefore, the appropriate classification is 'Transaction in Own Shares' (POS). The document length is short and focused on shareholding data related to a repurchase, fitting the POS category with high confidence.
2019-10-10 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.